Evidence map›Paper›PMID 23162133›Full record

ArticleThe Journal of infectious diseases2013

Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men.

Vikrant V Sahasrabuddhe, Philip E Castle, Stephen Follansbee, Sylvia Borgonovo, Diane Tokugawa, Lauren M Schwartz, Thomas S Lorey, Brandon J LaMere, Julia C Gage, Barbara Fetterman and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Association between Smoking and Anal Human Papillomavirus in the HPV Infection in Men Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Vikrant V SahasrabuddheDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA. vikrant.sahasrabuddhe@nih.gov
Philip E Castle
Stephen Follansbee
Sylvia Borgonovo
Diane Tokugawa
Lauren M Schwartz
Thomas S Lorey
Brandon J LaMere
Julia C Gage
Barbara Fetterman
Sean Boyle
Mark Sadorra
Scott Dahai Tang
Teresa M Darragh
Nicolas Wentzensen
Kaiser Permanente · USMaterials Systems (United States) · USNational Institutes of Health · USAlbert Einstein College of Medicine · USKaiser Permanente Oakland Medical Center · USNational Cancer Institute · USUniversity of California, San Francisco · US

Funding

Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
STRUCTURE AND STABILIZATION OF THE BACTERIAL NUCLEOIDZ01DK036120 · NIDDK · DIABETES, DIGESTIVE, KIDNEY DISEASES · PI ZIMMERMAN, STEVEN C. · 1998 to 2005
–
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

backgroundThe prevention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use.

methodsHPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines.

resultsHPV16 was the most common genotype overall (26.4% of cases) and among HGAIN cases (55%). Prevalence of multiple (≥ 2) carcinogenic HPV genotypes increased from 30.9% in cases of AIN grade <1 to 76.3% in cases of AIN grade 3 (P(trend) < .001). The fractions of HGAIN cases attributable to carcinogenic HPV16/18 targeted by currently licensed bivalent and quadrivalent HPV vaccines ranged from 12% to 61.5%, and the fractions attributable to carcinogenic HPV16/18/31/33/45/52/58 targeted by an investigational nonavalent HPV vaccine ranged from 39% to 89.4%.

conclusionsOur analytical framework allows estimation of HGAIN cases attributable to individual HPV genotypes in the context of multiple concurrent HPV infections, which are very common among HIV-infected MSM. Our results suggest that licensed and investigational HPV prophylactic vaccines have the potential to prevent a substantial proportion of HGAIN cases in this population.

Indexed as

GenotypeHIV InfectionsPapillomavirus InfectionsSexual BehaviorAdultAgedAnus NeoplasmsCarcinoma in SituCoinfectionCross-Sectional StudiesHumansMaleMiddle AgedNeoplasm GradingPapillomaviridaePapillomavirus VaccinesPapillomavirus Vaccines

Identifiers

PMID23162133
PMCPMC3537447
OpenAlexW2128275750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.